Effects of a Class III Antiarrhythmic Drug, Dofetilide, on the In Situ Canine Heart Assessed by the Simultaneous Monitoring of Hemodynamic and Electrophysiological Parameters.
Authors:
- Atsushi SugiyamaASAtsushi Sugiyama
- Kohji TamuraKTKohji Tamura
- Keitaro HashimotoKHKeitaro Hashimoto
- 1 January 1999
- journal article
- research article
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 81 (1) , 79-85
Abstract
The cardiovascular profile of dofetilide was examined using halothane-anesthetized, closed-chest in vivo canine model (n=6). Dofetilide was administered at the dose of 1, 10 or 100 microg/kg, i.v. over 10 min with a pause of 20 min. After the lowest infusion rate, no significant change was detected in any of the cardiovascular parameters. Infusion of 10 microg/kg dofetilide, which was close to the submaximal clinically effective antiarrhythmic dose, decreased the heart rate and prolonged the ventricular repolarization phase and refractory period. After the highest dose of dofetilide, the cardiac output and left ventricular contraction decreased during sinus rhythm, the latter of which was not changed during the constant heart rate of 150 beats/min, while the dose-related effects were observed on the heart rate, repolarization phase and refractory period. The afterload and preload to the left ventricle and AV nodal as well as intraventricular conductions were hardly affected even at 100 microg/kg, i.v. These results obtained in the in vivo canine model support the previous reports describing that dofetilide possesses a highly selective blocking property for I(Kr). Moreover, the absence of effects on the afterload and preload to the left ventricle and the cardiac conduction makes dofetilide favorable as an antiarrhythmic drug because it is often used for patients with moderate to severe left ventricular dysfunction.Keywords
This publication has 23 references indexed in Scilit:
- Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studiesClinical Cardiology, 1997
- Effects of Dofetilide, a Class III Antiarrhythmic Drug, on Various Ventricular Arrhythmias in DogsJournal of Cardiovascular Pharmacology, 1996
- Effects of the Antihypoxic and Neuroprotective Drug, Lubeluzole, on Repolarization Phase of Canine Heart Assessed by Monophasic Action Potential RecordingToxicology and Applied Pharmacology, 1996
- Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide.Circulation Research, 1993
- Dofetilide, A Novel Class III Antiarrhythmic AgentJournal of Cardiovascular Pharmacology, 1992
- Class III antiarrhythmic action by potassium channel blockade: dofetilide attenuates hypoxia induced electromechanical changesCardiovascular Research, 1992
- Cardiac Electrophysiologic and Inotropic Actions of New and Potent Methanesulfonanilide Class III Antiarrhythmic Agents in Anesthetized DogsJournal of Cardiovascular Pharmacology, 1991
- Rate and concentration‐dependent effects of UK‐68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and VmaxBritish Journal of Pharmacology, 1991
- Rate-Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK-68,798Journal of Cardiovascular Pharmacology, 1990
- Effects of UK-68,798, a novel class III antiarrhythmic agent, in conscious dogsJournal of Molecular and Cellular Cardiology, 1989